{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Protein Tyrosine Kinase/PTK > ImatinibCAS：152459-95-5
Molecular Formula：C29H31N7O
Molecular Weight：493.6
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：HPLC≥98%
Appearance：Off-white to light yellow Solid
Qty：
Size：
| CAS | 152459-95-5 |
| Name | Imatinib |
| Molecular Formula | C29H31N7O |
| Molecular Weight | 493.6 |
| Solubility | Soluble in DMSO ≥10mg/mL |
| Purity | HPLC≥98% |
| Appearance | Off-white to light yellow Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| EC | EINECS 604-855-6 |
| MDL | MFCD05662257 |
| SMILES | CN(CC1)CCN1CC2=CC=C(C(NC3=CC=C(C)C(NC4=NC(C5=CC=CN=C5)=CC=N4)=C3)=O)C=C2 |
| InChIKey | KTUFNOKKBVMGRW-UHFFFAOYSA-N |
| InChI | InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34) |
| PubChem CID | 5291 |
| Target Point | c-Kit;Bcr-Abl;v-Abl;PDGFR |
| Passage | Protein Tyrosine Kinase/RTK |
| Background | Imatinib is a tyrosine kinase inhibitor that inhibits c-Kit, Bcr-Abl and PDGFR. |
| Biological Activity | Imatinib 是一种酪氨酸激酶抑制剂，可抑制 c-Kit，Bcr-Abl 和 PDGFR。[1-6] |
| Data Literature Source | [1]. Heinrich MC， et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571， a selective tyrosine kinase inhibitor. Blood. 2000 Aug 1; 96 (3) :925-32. [2]. Guida T， et al. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res. 2007 Jun 1; 13 (11) :3363-9. [3]. Okuda K， et al. ARG tyrosine kinase activity is inhibited by STI571.Blood. 2001 Apr 15; 97 (8) :2440-8 [4]. Yao JC， et al. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res. 2007 Jan 1; 13 (1) :234-40. [5]. Sun XC， et al. Depletion of telomerase RNA inhibits growth of gastrointestinal tumors transplanted in mice. World J Gastroenterol. 2013 Apr 21; 19 (15) :2340-7. [6]. Yildiz C， et al. Effect of imatinib on growth of experimental endometriosis in rats. Eur J Obstet Gynecol Reprod Biol. 2016 Feb; 197:159-63 |
| Unit | Bottle |
| Specification | 10mg 10mM*1mL in DMSO 50mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
circ_0080145 Enhances Imatinib Resistance of Chronic Myeloid Leukemia by Regulating miR-326/ PPFIA1 Axis
Click to check >>Author：Che H; Ding H; Jia X.
IF：3.4000
Publish_to：Cancer Biother Radiopharm
PMID：32598170
Manual Download
